This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naresh, A. Articles by Jones, F. E. Search for Related Content PubMed PubMed Citation Articles by Naresh, A. Articles by Jones, F. E.

The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis

¹ Department of Molecular and Cellular Biology, Tulane University Health Sciences Center, New Orleans, Louisiana; ² Department of Pathology, University of Colorado Health Sciences Center, Aurora, Colorado; and ³ Department of Molecular and Cellular Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Frank E. Jones, Department of Pathology, University of Colorado Health Sciences Center, Mail Stop 8104, PO Box 6511, 12800 East 19th Avenue, Aurora, CO 80045. Phone: 303-724-4321; Fax: 303-724-3712; E-mail: Frank.Jones{at}UCHSC.edu.

Key Words: EGFR family • endocrine therapy • BCL-2 family • estrogen receptor • coactivators • breast cancer

Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance. Recent clinical evidence indicates that loss of expression of HER4 is an independent marker for tamoxifen resistance. In direct corroboration with clinical observations, suppression of HER4 expression in the tamoxifen-sensitive MCF-7 and T47D breast tumor cell lines resulted in resistance to tamoxifen-induced apoptosis. Furthermore, HER4 expression was lost in three independent MCF-7 models of acquired tamoxifen resistance. The HER4 intracellular domain (4ICD) is an independently signaling nuclear protein that functions as a potent ER coactivator. In addition, mitochondrial 4ICD functions as a proapoptotic BH3-only protein. Tamoxifen disrupts an estrogen-driven interaction between ER and 4ICD while promoting mitochondrial accumulation of the 4ICD BH3-only protein. BCL-2 inhibition of tamoxifen-induced apoptosis and tamoxifen activation of BAK, independent of BAX, further supports a role for 4ICD during tamoxifen-induced apoptosis. Finally, reintroduction of HER4, but not HER4 with a mutated BH3 domain, restores tamoxifen sensitivity to tamoxifen-resistant TamR cells in a xenograft model. Clinically, breast cancer patients with tumor expression of nuclear 4ICD responded to tamoxifen therapy with no clinical failures reported after 14 years of follow-up, whereas 20% of patients lacking nuclear 4ICD expression succumbed to their disease within 10 years of diagnosis. Our identification of the HER4/4ICD BH3-only protein as a critical mediator of tamoxifen action provides a clinically important role for 4ICD in human cancer and reveals a potential tumor marker to predict patient response to tamoxifen therapy. [Cancer Res 2008;68(15):6387–95]

This article has been cited by other articles:

				A. D. Thor, S. M. Edgerton, and F. E. Jones Subcellular Localization of the HER4 Intracellular Domain, 4ICD, Identifies Distinct Prognostic Outcomes for Breast Cancer Patients Am. J. Pathol., November 1, 2009; 175(5): 1802 - 1809. [Abstract] [Full Text] [PDF]

				S.-C. Wang and M.-C. Hung Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors Clin. Cancer Res., November 1, 2009; 15(21): 6484 - 6489. [Abstract] [Full Text] [PDF]

				D. Mitra, M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis, J. G. Parvani, S. M. Lesko, E. Brogi, and F. E. Jones An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance Mol. Cancer Ther., August 1, 2009; 8(8): 2152 - 2162. [Abstract] [Full Text] [PDF]